View Item 

Show simple item record

Abciximab‐Associated Thrombocytopenia After Previous Tirofiban‐Related Thrombocytopenia
dc.contributor.authorDorsch, Michael P.en_US
dc.contributor.authorMontague, Debbieen_US
dc.contributor.authorRodgers, Jo Ellenen_US
dc.contributor.authorPatterson, Camen_US
dc.date.accessioned2012-03-16T15:53:57Z
dc.date.available2012-03-16T15:53:57Z
dc.date.issued2006-03en_US
dc.identifier.citationDorsch, Michael P.; Montague, Debbie; Rodgers, Jo E.; Patterson, Cam (2006). "Abciximab‐Associated Thrombocytopenia After Previous Tirofiban‐Related Thrombocytopenia." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 26(3). <http://hdl.handle.net/2027.42/90080>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90080
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherThrombocytopeniaen_US
dc.subject.otherGPIIb‐IIIa Inhibitoren_US
dc.subject.otherGlycoprotein IIb‐IIIa Inhibitoren_US
dc.subject.otherDrug‐Induced Thrombocytopeniaen_US
dc.subject.otherAbciximaben_US
dc.subject.otherTirofibanen_US
dc.titleAbciximab‐Associated Thrombocytopenia After Previous Tirofiban‐Related Thrombocytopeniaen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pharmacy Services, University of Michigan Hospitals and Health Clinics, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherSchools of Pharmacy University of North Carolina, Chapel Hill, North Carolinaen_US
dc.contributor.affiliationotherMedicine University of North Carolina, Chapel Hill, North Carolina.en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90080/1/phco.26.3.423.pdf
dc.identifier.doi10.1592/phco.26.3.423en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferencePURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST‐segment elevation. N Engl J Med 1998; 339: 436 – 43.en_US
dc.identifier.citedreferenceEPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high‐risk coronary angioplasty. N Engl J Med 1994; 330: 956 – 61.en_US
dc.identifier.citedreferenceRESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445 – 53.en_US
dc.identifier.citedreferenceESPIRIT Study Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo‐controlled trial. Lancet 2000; 356: 2037 – 44.en_US
dc.identifier.citedreferenceKereiakes, D.J., Essell, J.H., Abbottsmith, C.W., et al. Abciximab‐associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusions. Am J Cardiol 1996; 78: 1161 – 3.en_US
dc.identifier.citedreferenceNguyen, N., Salib, H., Mascarenhas, D.A.N., et al. Acute profound thrombocytopenia without bleeding complications after readministration. J Invasive Cardiol 2001; 13: 56 – 8.en_US
dc.identifier.citedreferenceNational Institutes of Health. Platelet transfusion therapy. NIH consensus statement online, October 6–8, 1986. Available from http:www.consensus.nih.gov. Accessed May 23, 2005.en_US
dc.identifier.citedreferenceWazny, L.D., Ariano, R.E.. Evaluation and management of drug‐induced thrombocytopenia in the acutely ill patient. Pharmacotherapy 2000; 20: 292 – 307.en_US
dc.identifier.citedreferenceRao, J., Mascarenhas, D.A.N.. Successful use of eptifibatide as an adjunct to coronary stenting in a patient with abciximab‐associated acute profound thrombocytopenia. J Invasive Cardiol 2001; 13: 471 – 3.en_US
dc.identifier.citedreferenceDesai, M., Lucore, C.L.. Uneventful use of tirofiban as an adjunct to coronary stenting in a patient with a history of abciximab‐associated thrombocytopenia 10 months earlier. J Invasive Cardiol 2000; 12: 109 – 12.en_US
dc.identifier.citedreferenceBerkowitz, S.D., Harrington, R.A., Rund, M.M., Tcheng, J.E.. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997; 95: 809 – 13.en_US
dc.identifier.citedreferenceCurtis, B.R., Swyers, J., Divgi, A., et al. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab‐coated platelets. Blood 2002; 99: 2054 – 9.en_US
dc.identifier.citedreferenceBougie, D.W., Wilker, P.R., Wuitschick, E.D., et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand‐occupied GPIIb/IIIa. Blood 2002; 100: 2071 – 6.en_US
dc.identifier.citedreferenceAster, R.H.. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 2005; 127: 53S – 9.en_US
dc.identifier.citedreferenceVan den Bemt, P.L., Meyboom, R.H., Egberts, A.C.. Drug‐induced immune thrombocytopenia. Drug Saf 2004; 27: 1243 – 52.en_US
dc.identifier.citedreferenceReoPro Readministration Registry Investigators. Final results of the ReoPro readministration registry. Am J Cardiol 2004; 93: 979 – 84.en_US
dc.identifier.citedreferencePedersen‐Njergaard, U., Andersen, M., Hansen, P.B.. Drug‐induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy. Eur J Clin Pharmacol 1997; 52: 183 – 9.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.26.3.423.pdf
Size:
64.94KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.